TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Annual Earnings

TLSI·Reported May 15, 2025·Before market open

TriSalus Life Sciences, Inc. reported Q1 2025 revenue of $9.2M (+42.0% YoY), beat analyst consensus of $9.1M by $72.1K. Diluted EPS came in at $-0.33 (+38.9% YoY), missed the $-0.20 consensus by $0.13.

Revenue
$9.2Mbeat by $72.1K
Consensus: $9.1M
Diluted EPS
$-0.33missed by $0.13
Consensus: $-0.20
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001826667-25-000030

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about TriSalus Life Sciences, Inc.'s Q1 2025 earnings report.

TriSalus Life Sciences, Inc. (TLSI) reported Q1 2025 earnings on May 15, 2025 before market open.

TriSalus Life Sciences, Inc. reported revenue of $9.2M and diluted EPS of $-0.33 for Q1 2025.

Revenue beat the consensus estimate of $9.1M by $72.1K. EPS missed the consensus estimate of $-0.20 by $0.13.

Compared to the same quarter a year prior, revenue grew 42.0% from $6.5M a year earlier and diluted EPS grew 38.9% from $-0.54.

You can read the 10-K periodic report (0001826667-25-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.